Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis.
Di Liu, Na Yuan, Guimei Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian random-effects network meta-analysis compared six biologic DMARD classes for radiographic progression in rheumatoid arthritis, using randomized controlled trials and change in modified Total Sharp Score (mTSS) at 12 months as the primary outcome. Across 27 trials involving 11,650 patients, all classes inhibited mTSS progression versus placebo. Compared with TNF-α inhibitors, B-cell depleting agents showed greater inhibition (MD = -18.46, 95% CI -20.86 to -16.06), as did IL-23 inhibitors (MD = -18.14, 95% CI -21.11 to -15.16). These classes ranked highest, but the authors considered the ranking hypothesis generating.
Key findings
- All six biologic DMARD classes significantly inhibited mTSS progression versus placebo.
- Compared with TNF-α inhibitors, B-cell depleting agents had MD = -18.46, 95% CI -20.86 to -16.06; IL-23 inhibitors had MD = -18.14, 95% CI -21.11 to -15.16.
- For bone erosion, IL-17, B-cell depleting, IL-6 receptor and T-cell agents—but not IL-23 inhibitors—were superior to TNF-α inhibitors.
- Serious adverse events did not differ from placebo in the 10 RCTs reporting this outcome.
Why it matters
Radiographic progression represents irreversible joint damage, so comparative evidence on structural protection can inform understanding of biologic treatment effects in RA. The analysis suggests that several classes may differ in radiographic outcomes and that structural and clinical response rankings are not necessarily identical. However, the comparative estimates and rankings should be interpreted cautiously because some comparisons relied on few trials.
What to keep in mind
Several comparisons rested on few trials, making the ranking hypothesis generating.